PHARMACY AND THERAPEUTICS COMMITTEE
MEDICARE MEETING MINUTES
PPO-POS, HMO-POS, HMO-SNP
October 26, 2023

Attendance: *Microsoft Teams Meeting*
Rakel Beall-Wilkins, Magellan Health; Connie Chan, Staff/Clinical Pharmacist; Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Enterprise Director Clinical Pharmacy programs, Jefferson Health; Merleen Harris-Williams, Medical Director; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Student Intern; Lawrence Jones, Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Christina Le, Pharmacy Student Intern; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Karleen Melody; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: *Justin Bittner, Medical Director; Gary Bledsoe, Staff/Clinical Pharmacist; Kay Chan, Manager Pharmacy Benefit Design and Audits; Demian Elder, Medical Director; Oluwatoyin Fadeyibi, Community Behavior Health; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist*

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
Minutes Review/Approval	*D. Dolores presented the minutes from the August 2023 meeting to the Committee for review.*	*The Committee approved the minutes from our last meeting as presented.*	*D. Dolores*	*Resolved*	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
2024 HMO/PPO Updates	*H. McCaffrey provided updates on the HMO/PPO plans for 2024*		*H. McCaffrey*	*Informational*	
Policies & Procedures for HMO and PPO	*D. Dolores presented the following policies and procedures* • *Coverage Determination and Prior Authorization* ○ *Added quarterly review for cases and explanations* • *FDR Oversight* • *Medication Quality Assurance* • *Pharmacy & Therapeutics Committee* • *Transition Policy*	*Policies and Procedures for HMO and PPO were reviewed..*	*D. Dolores*	*Informational*	
2024 HMO/PPO MTM Program	*K. Koerwitz presented the 2024 HMO/PPO MTM Program*		*K. Koerwitz*	*Informational*	

II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
2024 Prior Authorization Criteria – CMS Outlier Review	*The Committee reviewed the 2024 Prior Authorization Criteria – CMS Outlier Review. The Committee approved as presented:* • *Apomorphine Hcl* • *Deferiprone* • *Dupixent* • *Endothelin Receptor Antagonists* • *Skyrizi* • *Stelara*	*The Committee approved the 2024 Prior Authorization Criteria – CMS Outlier Review. It will be sent to CMS for approval. (See attached for voting detail)*	*F. Vaisberg* *S. Jackson* *J. Crawford* *J. Zubrzycki*	*Resolved*	
Additions Protected Class (Fall Limited Window) - 2024	*The Committee reviewed the Additions Protected Class (Fall Limited Window). The Committee approved as presented:* ***Drug Name*** / ***6-Tier Formulary (PPO, HMO-POS)*** / ***1-Tier Formulary (HMO-SNP)*** *Vigadrone 500mg tablet* / *T5* / *T1, NDS*	*The Committee reviewed the Additions Protected Class (Fall Limited Window). It will be sent to CMS for approval. (See attached for voting detail)*	*F. Vaisberg*	*Resolved*	
Additions Non-Protected Class (Fall Limited Window) - 2024	*The Committee reviewed the Additions Non-Protected Class (Fall Limited Window). The Committee approved as presented:* ***Drug Name*** / ***6-Tier Formulary (PPO, HMO-POS)*** / ***1-Tier Formulary (HMO-SNP)***	*The Committee reviewed the Additions Non-Protected Class*	*F. Vaisberg*	*Resolved*	

<table>
<tr><th>TOPIC</th><th colspan="3">DISCUSSION</th><th>ACTIONS</th><th>RESPONSIBLE PARTY</th><th>RESOLVED/ PENDING</th><th>DUE DATE</th></tr>
<tr><td></td><td>Depo-Testosterone 200 mg/mL</td><td>T2, Injectable Testosterone Products PA</td><td>T1, Injectable Testosterone Products PA</td><td rowspan="11">(Fall Limited Window). It will be sent to CMS for approval. (See attached for voting detail)</td><td rowspan="11"></td><td rowspan="11"></td><td rowspan="11"></td></tr>
<tr><td></td><td>Depo-Testosterone 100 mg/mL</td><td>T2, Injectable Testosterone Products PA</td><td>T1, Injectable Testosterone Products PA</td></tr>
<tr><td></td><td>Abrysvo injection</td><td>T1</td><td>T1</td></tr>
<tr><td></td><td>Arexvy injection</td><td>T1</td><td>T1</td></tr>
<tr><td></td><td>Austedo XR Patient Titration 6 & 12 & 24 mg tber thpk</td><td>T5, Austedo PA</td><td>T1, Austedo PA</td></tr>
<tr><td></td><td>Multiple Electro Type 1 Ph 7.4 Solution</td><td></td><td>T4</td></tr>
<tr><td></td><td>Tiotropium 0.018 mg inhalation powder</td><td>T3</td><td>T1</td></tr>
<tr><td></td><td>Vancomycin HCl 5 gm recon soln</td><td>T4</td><td>T1</td></tr>
<tr><td></td><td>Kourzeq 0.1 % paste</td><td>T2</td><td>T1</td></tr>
<tr><td></td><td>Lidocan 5% patch</td><td>T2</td><td>T1</td></tr>
<tr><td>Formulary Removals (May FRF, Summer Update Window) - 2024</td><td colspan="3">The Committee reviewed the Formulary Removals (May FRF, Summer Update Window). The Committee approved as presented:
Flovent Diskus
Flovent HFA
Penicillin G Procaine 600000 unit/ml suspension</td><td>The Committee approved the Formulary Removals (May FRF, Summer Update Window). It will be sent to CMS for approval. (See attached for voting detail)</td><td>F. Vaisberg</td><td>Resolved</td><td></td></tr>
<tr><td rowspan="3">Brand Removals (generic equivalent added to the formulary) - 2024</td><td colspan="3">The Committee reviewed the Brand Removals. The Committee approved as presented:</td><td rowspan="3">The Committee approved the Brand Removals. It will be sent to CMS for approval. (See attached for voting detail)</td><td rowspan="3">F. Vaisberg</td><td rowspan="3">Resolved</td><td rowspan="3"></td></tr>
<tr><td>Drug Name</td><td>6-Tier Formulary (PPO, HMO-POS)</td><td>1-Tier Formulary</td></tr>
<tr><td>Plasma-Lyte 148 Solution</td><td>T4</td><td>T1</td></tr>
<tr><td>Quantity Limits - 2024</td><td colspan="3">The Committee reviewed the Quantity Limits. The Committee approved as presented:
Vigadrone 500mg tablet - 180/30 days
Tiotropium 0.018 mg inhalation powder - 30/30 days</td><td>The Committee approved the Quantity Limits. It will be sent to CMS for approval. (See</td><td>F. Vaisberg</td><td>Resolved</td><td></td></tr>
</table>

<table>
<tr><th>TOPIC</th><th>DISCUSSION</th><th>ACTIONS</th><th>RESPONSIBLE PARTY</th><th>RESOLVED/ PENDING</th><th>DUE DATE</th></tr>
<tr><td></td><td>Austedo XR Patient Titration 6 & 12 & 24 mg tber thpk - 42/28 days
Lidocan 5% patch - 90/30 days</td><td>attached for voting detail)</td><td></td><td></td><td></td></tr>
<tr><td>Formulary Additions - 2023</td><td>The Committee reviewed the Formulary Additions - 2023. The Committee approved as presented:<table><tr><th>Drug Name</th><th>Prime/Complete/ Silver/Platinum</th><th>Special</th></tr><tr><td>Akeega 100-500 MG TAB</td><td>T5, Oral Oncology PA</td><td>T1, Oral Oncology PA</td></tr><tr><td>Akeega 50-500 MG TAB</td><td>T5, Oral Oncology PA</td><td>T1, Oral Oncology PA</td></tr><tr><td>Depo-Testosterone 100 Mg/Ml Solution</td><td>T2</td><td>T1</td></tr><tr><td>Depo-Testosterone 200 Mg/Ml Solution</td><td>T2</td><td>T1</td></tr><tr><td>Kalydeco 5.8 mg packet</td><td>T5, Kalydeco PA</td><td>T1, Kalydeco PA</td></tr><tr><td>Phenytek cap 200mg</td><td>T1</td><td>T1</td></tr><tr><td>Phenytek cap 300mg</td><td>T1</td><td>T1</td></tr><tr><td>Vanflyta 17.7 MG TAB</td><td>T5, Oral Oncology PA</td><td>T1, Oral Oncology PA</td></tr><tr><td>Vanflyta 26.5 MG TAB</td><td>T5, Oral Oncology PA</td><td>T1, Oral Oncology PA</td></tr><tr><td>Yargesa 100 mg cap</td><td>T5</td><td>T1</td></tr></table></td><td>The Committee approved the Formulary Additions - 2023. It will be sent to CMS for approval. (See attached for voting detail)</td><td>F. Vaisberg</td><td>Resolved</td><td></td></tr>
<tr><td>Additions Non-Protected Class (Aug/Sept FRF) - 2023</td><td>The Committee reviewed the Additions Non-Protected Class (Aug/Sept FRF). The Committee approved as presented:<table><tr><th>Drug Name</th><th>Prime/Complete/ Silver/Platinum</th><th>Special</th></tr><tr><td>Abrysvo injection</td><td>T1</td><td>T1</td></tr><tr><td>Arexvy injection</td><td>T1</td><td>T1</td></tr><tr><td>Multiple Electro Type 1 Ph 7.4 Solution</td><td></td><td>T4</td></tr></table></td><td>The Committee attached for voting detail) approved the Additions Non-Protected Class (Aug/Sept FRF). It will be sent to CMS for approval. (See</td><td>F. Vaisberg</td><td>Resolved</td><td></td></tr>
<tr><td>Removals from Formulary (Aug/Sept FRF) – will remain on formulary until the end of the benefit year</td><td>The Committee reviewed the Formulary Removals (Aug/Sept FRF). The Committee approved as presented:<table><tr><th>Drug Name</th><th>Prime/Complete/ Silver/Platinum</th><th>Special</th></tr><tr><td>Avita 0.025 % Cream</td><td>T4, Topical Retinoids PA</td><td>T1, Topical Retinoids PA</td></tr><tr><td>Nevirapine Er 100 Mg Tab Er 24h</td><td>T4, QL 120/30 days</td><td>T1, QL 120/30 days</td></tr><tr><td>Penicillin G Procaine 600000 Unt/Ml</td><td>T4</td><td>T1</td></tr></table></td><td>The Committee approved the Formulary Removals (Aug/Sept FRF). It will be sent to CMS for approval. (See attached for voting detail)</td><td>F. Vaisberg</td><td>Resolved</td><td></td></tr>
</table>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
Quantity Limits - 2023	*The Committee reviewed the Quantity Limits. The Committee approved as presented:* • *Kalydeco 5.8 mg packet - 56/28 days* • *Yargesa 100 mg cap - 90/30 days*	*The Committee approved the Quantity Limits. It will be sent to CMS for approval. (See attached for voting detail)*	*F. Vaisberg*	*Resolved*	
III. New Drug Review	*The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:* • *Keytruda (pembrolizumab) for Injection* • *Opdivo (nivolumab) Injection* • *Braftovi (encorafenib) Capsules* • *Abrilada (adalimumab-afzb) Injection* • *Exxua* (gepirone) Extended-Release Tablets* • *Bosulif (bosutinib) Tablets* • *Ojjaara* (momelotinib) Tablets* • *Aphexda* (motixafortide) Lyophilized Powder for Injection* • *The following medications are Formulary with new FDA-approved indications:* • *N/A* *The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:* • *Penbray* (meningococcal groups A, B, C, W, and Y vaccine) Injection* • *Zilbrysq* (zilucoplan) Injection* • *Xphozah* (tenapanor) Tablets* • *Qlosi* (pilocarpine hydrochloride) Ophthalmic Solution - formerly CSF-1* • *Bimzelx* (bimekizumab-bkzx) Injection* • *Velsipity* (etrasimod) Tablets* • *Cosentyx (secukinumab) Injection* • *Zoryve (roflumilast) Cream* • *Empaveli (pegcetacoplan) Injection* • *Entyvio (vedolizumab) Injection* • *Tofidence* (tocilizumab-bavi) Injection* • *Rivfloza* (nedosiran) Injection* • *Technegas* (technetium Tc 99m carbon) Inhalation Aerosol*	*Per CMS regulations, "The P&T committee will make a reasonable effort to review a new FDA approved drug product (or new FDA approved indication) within 90 days of its release onto the market and will make a decision on each new FDA approved drug product (or new FDA approved indication) within 180 days of its release onto the market, or a clinical justification will be provided if this timeframe is not met. Formularies must include substantially all drugs in the six protected categories that are FDA approved by the last CMS specified HPMS formulary upload date for the upcoming contract*	*J. Steffan*	*Resolved*	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
	• *Pombiliti* (cipaglucosidase alfa-atga) Lyophilized Powder for Injection* • *Opfolda* (miglustat) Capsules* • *Ryzumvi* (phentolamine mesylate) Ophthalmic Solution - formerly Nyxol* • *Likmez* (metronidazole) Oral Suspension* • *Reblozyl (luspatercept-aamt) Injection* • *Tyruko* (natalizumab-sztn) Injection* • *Veopoz* (pozelimab-bbfg) Injection* • *Ingrezza (valbenazine) Capsule* • *Eylea HD* (aflibercept) Injection* *(* Previously discussed in New Drug Review for Medicaid)*	*year. New drugs or newly approved uses for drugs within the six classes that come onto the market after the CMS specified formulary upload date will be subject to an expedited P&T committee review. The expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement. At the end of the 90 day period, these drugs must be added to Part D plan formularies." (See attached for voting detail.)*			

IV. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2024.

11/14/23

__Danielle Dolores, Director of Pharmacy Services Date: _____

APPENDIX I: VOTING GRID

	Danielle Dolores, PharmD	George Downs, PharmD	Lawrence Jones, RPh	Karleen Melody, PharmD	Tania Kolev, MD	Hannah McCaffrey	Sanjiv Raj	Brian Swift	Kaylei Koerwitz	Heather Scheckner	Merleen Harris-Williams, MD	Justin Bittner, MD	Demian Elder, MD	Edgar Chou, MD	Ramesh Vangala, PharmD	Comments
Minutes Review/Approval	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	*August 2023*
2024 Prior Authorization Criteria – CMS Outlier Review	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Additions Protected Class (Fall Limited Window) - 2024	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Additions Non-Protected Class (Fall Limited Window) - 2024	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Formulary Removals (May FRF, Summer Update Window) - 2024	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Brand Removals (generic equivalent added to the formulary) - 2024	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Quantity Limits - 2024	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Formulary Additions - 2023	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Additions Non-Protected Class (Aug/Sept FRF) - 2023	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
Removals from Formulary (Aug/Sept FRF)	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	

	Danielle Dolores, PharmD	George Downs, PharmD	Lawrence Jones, RPh	Karleen Melody, PharmD	Tania Kolev, MD	Hannah McCaffrey	Sanjiv Raj	Brian Swift	Kaylei Koerwitz	Heather Scheckner	Merleen Harris-Williams, MD	Justin Bittner, MD	Demian Elder, MD	Edgar Chou, MD	Ramesh Vangala, PharmD	Comments
– will remain on formulary until the end of the benefit year																
Quantity Limits - 2023	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	
New Drug Review	A	A	A	A	A	A	A	A	A	E	A	E	E	A	A	

*A = Approved as presented * R = Rejected * E = Excused from meeting * P = Precluded from vote due to conflict of interest